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Background: Trastuzumab resistance is almost inevitable in the management of human epidermal growth factor
receptor (HER) 2 positive breast cancer, in which phosphatase and tensin homolog deleted from chromosome 10
(PTEN) loss is implicated. Since metadherin (MTDH) promotes malignant phenotype of breast cancer, we sought to
define whether MTDH promotes trastuzumab resistance by decreasing PTEN expression through an NFκB-dependent
pathway.
Methods: The correlations between MTDH and PTEN expressions were analyzed both in HER2 positive breast cancer
tissues and trastuzumab resistant SK-BR-3 (SK-BR-3/R) cells. Gene manipulations of MTDH and PTEN levels by knockdown
or overexpression were utilized to elucidate molecular mechanisms of MTDH and PTEN implication in trastuzumab
resistance. For in vivo studies, SK-BR-3 and SK-BR-3/R cells and modified derivatives were inoculated into nude mice alone
or under trastuzumab exposure. Tumor volumes, histological examinations as well as Ki67 and PTEN expressions were
revealed.
Results: Elevated MTDH expression indicated poor clinical benefit, shortened progression free survival time, and was
negatively correlated with PTEN level both in HER2 positive breast cancer patients and SK-BR-3/R cells. MTDH
knockdown restored PTEN expression and trastuzumab sensitivity in SK-BR-3/R cells, while MTDH overexpression
prevented SK-BR-3 cell death under trastuzumab exposure, probably through IκBα inhibition and nuclear translocation
of p65 which subsequently decreased PTEN expression. Synergized effect of PTEN regulation were observed upon
MTDH and p65 co-transfection. Forced PTEN expression in SK-BR-3/R cells restored trastuzumab sensitivity. Furthermore,
decreased tumor volume and Ki67 level as well as increased PTEN expression were observed after MTDH knockdown
in subcutaneous breast cancer xenografts from SK-BR-3/R cells, while the opposite effect were found in grafts from
MTDH overexpressing SK-BR-3 cells.
Conclusions: MTDH overexpression confers trastuzumab resistance in HER2 positive breast cancer. MTDH mediates
trastuzumab resistance, at least in part, by PTEN inhibition through an NFκB-dependent pathway, which may be utilized
as a promising therapeutic target for HER2 positive breast cancer.
Keywords: Metadherin (MTDH), Trastuzumab, Drug resistance, Human epidermal growth factor receptor 2 (HER2),
Breast cancer, Phosphatase and tensin homologue deleted from chromosome 10 (PTEN), Nuclear factor kappa B (NFκB)* Correspondence: hylcardiology@163.com; manjiangxie@hotmail.com;
doctor_xxd@163.com
†Equal contributors
5Department of Cardiology, General Hospital of Shenyang Military Area
Command, Shenyang 110016, P. R. China
6Key Laboratory of Aerospace Medicine, Ministry of Education, Fourth Military
Medical University, Xi’an 710032, P. R. China
1Department of Oncology, General Hospital of Shenyang Military Area
Command, Shenyang 110016, P. R. China
Full list of author information is available at the end of the article
© 2014 Du et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Du et al. BMC Cancer 2014, 14:869 Page 2 of 13
http://www.biomedcentral.com/1471-2407/14/869Background
The human epidermal growth factor receptor (HER) 2
oncogene from the epidermal growth factor receptor
(EGFR) family encodes a receptor tyrosine protein kinase
(RTK) that involves in crucial adaptations of cell function
under pathophysiological processes [1]. However, HER2
overexpression in cancer cells promotes a malignant pheno-
type, presented as increased proliferation and invasion, re-
duced apoptosis, accelerated angiogenesis and enhanced
resistance to anticancer therapy [2,3]. In approximately 20%
of invasive breast cancer patients, HER2 overexpression oc-
curs and correlates with shortened disease free survival and
overall survival [4,5].
Trastuzumab, a humanized antibody targeting the extra-
cellular domain of HER2, has been approved for the treat-
ment of HER2-overexpressing breast cancer in both the
metastatic and adjuvant settings [6]. Currently, combin-
ation therapy using trastuzumab and conventional chemo-
therapeutic agents were recommended as first line therapy
for the management of HER2 positive breast cancer, which
significantly improves patient outcomes [7,8]. However,
about 15% of patients with early-stage HER2 positive breast
cancer progress to metastatic disease. Besides, most
patients who achieve an initial response will develop refrac-
tory trastuzumab resistance within one year [9]. Despite
several mechanisms of trastuzumab resistance have been
proposed, including loss of PTEN activity and up-
regulation of the PI3K/Akt pathway, accumulation of a
truncated form of the HER2 receptor (p95-HER2), failure
to elicit an appropriate immune response and increased sig-
naling from alternative pathways such as EGFR and IGF-1R
[10,11], the detailed mechanism implicated in trastuzumab
resistance remains unclear.
Metadherin (MTDH), also named as astrocyte elevated
gene-1 (AEG-1) and lysine-rich CEACAM1 coisolated
(LYRIC), is a 64 kDa single trans-membrane protein ori-
ginally cloned as a human immunodeficiency virus (HIV)-
1-inducible transcript in primary human fetal astrocytes
[12]. MTDH is intensively expressed in many types of can-
cer, including hepatocellular carcinoma (HCC), breast,
prostate, gastric, renal and colorectal cancer, non-small
cell lung cancer, esophageal squamous cell carcinoma and
glioma, actively participating in cancer invasion, angiogen-
esis, autophagy and metastasis formation [13-17]. Down-
regulation of MTDH reduces cell proliferation and increases
apoptosis [18], while MTDH overexpression indicates poor
prognosis in invasive breast cancer [19,20]. Besides, MTDH
promotes both chemo- and tamoxifen-resistance [21-25].
However, whether MTDH mediates trastuzumab resistance
has not been investigated.
PTEN (phosphatase and tensin homologue deleted
from chromosome 10) dephosphorylates the 3’-sites of
the phosphoinositides PIP2 and PIP3 that involve in the
activation of PI3K/Akt pathway, playing an importantrole in cellular survival. PTEN expression can be sup-
pressed by tumor necrosis factor-(TNF) through activating
NFκB pathway. NFκB comprises a transactivation part
RelA/p65 and a DNA-binding part p50 (NFκB1) and p52
that combine with inhibitor of NFκB (IκB) and resides in
the cytoplasm and remains inactive in unstimulated cir-
cumstances. Upon stimulation, IκB phosphorylation release
NFκB, which translocates into the nucleus and activates tar-
get genes against apoptosis and death.
In the present study, we tested the hypothesis that
MTDH mediates trastuzumab resistance by decreasing
PTEN expression through NFκB dependent pathway.
Methods
Patients and tissue samples
This study was approved by the Ethics Committee of Gen-
eral Hospital of Shenyang Military Area Command. HER2
positive tissue specimens confirmed by immunohistochem-
istry were collected with informed consent from 118 female
breast cancer patients treated in aforementioned hospital be-
tween 2006 and 2011. All the patients were recommended
to use trastuzumab-based therapy and 36 patients with ad-
vanced disease received trastuzumab-based regimen for the
first-line therapy (TCH regimen: Taxotere 75 mg/m2, Carbo-
platin AUC 6 mg/ml/min, and Herceptin 8 mg/kg as initial
dose reduced to 6 mg/kg every 3 weeks). Clinical and patho-
logical classification and staging were evaluated according to
the American Joint Committee on Cancer criteria. Clinical
benefit rate from trastuzumab, defined as patients having a
complete response, partial response, or stable disease ≥
6 month, was evaluated by the Response Evaluation Criteria
in Solid Tumors (RECIST, version 1.1). Progression-free
survival (PFS) were calculated from the onset of treatment
to disease progression or death. Tissues were embedded
for immunohistochemical analysis of MTDH and PTEN
expression.
Histological examination
Hematoxylin and eosin (HE) staining for histological
analysis was implemented according to previously re-
ported protocol [26]. Briefly, 4-μm sections were stained
with hematoxylin and eosin and then observed under
Eclipse 80i microscope (Nikon Corp., Japan).
Immunohistochemical analysis was carried out pursuant
to the manuals of streptavidin-peroxidase-biotin reagent
Kit (ZSBio, Beijing, China). Briefly, 4-μm sections were
rehydrated and incubated with anti-MTDH and anti-PTEN
antibodies (Cell Signaling Technology, MA, USA) or PBS
at 4°C overnight, followed by sequential incubation with bi-
otinylated secondary antibody, streptavidin-horseradish per-
oxidase complex and diaminobenzidine (DAB). Then slides
were counterstained with hematoxylin, dehydrated, and
mounted. Sections were observed and imaged under light
microscope.
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ated based on the staining intensity (SI) and percentage of
positively stained tumor cells (PP). SI was defined as: 0
(no staining); 1 (weak staining); 2 (moderate staining) and
3 (strong staining). PP was graded according to the follow-
ing criteria: 0 (no positive tumor cells); 1 (1%-10% positive
tumor cells); 2 (11%-50% positive tumor cells); 3 (51%-
70% positive tumor cells); and 4(>70% positive tumor
cells). The immunoreactive score (IRS) was calculated as
follows: IRS = SI × PP. Low expression was defined as an
IRS of 3 or less.
Cell culture and development of trastuzumab resistance
Human breast cancer cell line SK-BR-3 was obtained from
the American Type Culture Collection (ATCC, Manassas,
VA, USA). Culture medium was RPMI 1640 containing
10% fetal bovine serum (Gibco, NY, USA), supplemented
with 100U/mL penicillin and 100 μg/mL streptomycin
(Sigma-Aldrich, MO, USA). Cells were cultured in humidi-
fied atmosphere containing 5% CO2 at 37°C. Resistant cells
(SK-BR-3/R) were developed by culturing parental SK-BR-3
cells in the presence of 5 μg/ml trastuzumab (Genentech,
CA, USA) for 8 months. Trastuzumab was dissolved in
sterile apyrogen water and stored at 4°C before use.
RNA extraction and real-time RT-PCR
Total RNA was isolated using TRIzol reagent (Life Tech-
nologies, CA, USA) and reversely transcribed with a
reverse transcription polymerase chain reaction (PCR) kit
(Takara, Dalian, China) as described by the manufacturers.
Real-time PCR was done using specific primers (MTDH:
5’-AAATAGCCAGCCTATCAAGACTC-3’ and 5’-TTCA
GACTTGGTCTGTGAAGGAG-3’; PTEN: 5’- AATCCTC
AGTTTGTGGTCT-3’ and 5’-GGTAACGGCTGAGGGA
ACT-3’; GAPDH: 5’-GACTCATGACCACAGTCCATG
C-3’ and 5’-AGAGGCAGGGATGATGTTCTG-3’) with
the QuantiTect SYBR Green PCR Kit (Takara, Dalian,
China) as described elsewhere [27].
Western blot analysis
Proteins were extracted using NE-PER® Nuclear and Cyto-
plasmic Extraction Reagents (Pierce, Rockford, IL, USA)
containing protease inhibitors and phosphatase inhibitors.
Proteins were quantified using the BCA protein assay kit
(Thermo, IL, USA) and separated using NuPAGE 4-12%
Bis-Tris gel (Invitrogen, CA, US). After transferred to
PVDF membrane (Millipore, MA, USA), proteins were
detected by the following antibodies: mouse anti MTDH
mAb, mouse anti PTEN mAb, rabbit anti AKT mAb,
rabbit anti p-AKT(Ser473) mAb (Cell Signaling Technol-
ogy, MA, USA), β-actin antibody (Abcam, UK) and anti-
mouse or anti-rabbit secondary antibody (Abcam, UK).
Blots were finally visualized using an enhanced chemilu-
minescence detection kit (Thermo, IL, USA).Immunofluorescence staining
Cells were seeded on glass cover slips and fixed with 4%
formaldehyde in PBS. Immunofluorescence staining was
done with anti-MTDH, anti-PTEN, anti-p-AKT and anti-
p65 (Cell Signaling Technology, MA, USA) antibodies.
Slips were incubated with indicated primary antibodies,
followed by incubation with fluorescein isothiocyanate-
conjugated goat anti-mouse secondary antibody or
Texas Red-conjugated goat-anti-rabbit secondary anti-
body (Abcam, Cambridge, MA, USA). Then slips were
counterstained with 4’,6-diamidino-2- phenylindole dihy-
drochloride (DAPI) solution (Sigma, St Louis, MO, USA).
Slips were observed and imaged under fluorescence
microscope.Cell proliferation assay
Cell proliferation was measured by methylthiazolyltetrazo-
lium (MTT) assay and 5-ethynyl-2′-deoxyuridine (EdU)
incorporation assay. For MTT assay, cells were seeded at a
density of 3000 cells per well in 96-well plates and regrew
for 24 h. Varied concentrations of trastuzumab (0, 0.63,
1.25, 2.5, 5, 10, 20 μg/ml) or equal volumes of sterile
apyrogen water were added and cocultured for 1 to 7 days.
Cells were incubated subsequently with 5 mg/ml MTT
(Sigma) and 150ul of dimethylsulfoxide (DMSO). The ab-
sorbance was measured at 570 nm. For EdU incorporation
assay, staining procedure was performed using Cell-Light™
EdU Apollo® 488 In Vitro Imaging Kit (RBbio, Guangzhou,
China). Briefly, cells in 96-well plates were exposed to
5 μg/ml trastuzumab for 4 days. After incubation with
EdU working solution for 2 h, cells were stained with
DAPI solution. EdU-labeled cells was counted in ten ran-
domly selected fields under fluorescent microscope Olym-
pus BX51. Cell proliferation rate was calculated as a
percentage to the control group.TUNEL assay
To detect cell apoptosis, terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end labeling (TUNEL) assay
was performed using the In Situ Cell Death Detection Kit
according to the instruction manual of the manufacturer
(Roche, Mannheim, Germany). Briefly, samples were fixed
using 4% paraformaldehyde. After membrane penetration
with 0.1% Triton X-100 and PBS wash, samples were incu-
bated with TUNEL reaction mixture for 60 min at 37°C.
DAPI was utilized for nuclei counterstain. Then samples
were observed and imaged under fluorescence micro-
scope. Cells transfected GFP-PTEN were treated with
POD substrates and diaminobenzidine (DAB) after incu-
bation with TUNEL reaction mixture. Then cells were
counterstained with hematoxylin and imaged under light
microscope. Apoptosis rate was calculated as a percentage
to the control group.
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MTDH knockdown was achieved with a pGV112-MTDH-
shRNA system (Genechem Co. Ltd. Shanghai, China)
targeting the following sequence: 5’-CAGAAGAAGAA
GAACCGGA-3’ as reported by Yoo’s group [28]. Vectors
expressing a non-targeting scrambled shRNA were used as
control. MTDH overexpression was achieved using the
retroviral expression vector pReceiver-Lv105 (GeneCopoeia
Rockville, MD, USA). Viruses were generated and used to
infect target cells as previously described [29]. The stably
infected cells were selected with 0.5 μg/ml puromycin.
Western blot analysis was performed to validate the knock-
down or overexpression of MTDH.
The p-CMV/Neo-PTEN and p-CMV/Neo-p65 expression
constructs were purchased from GeneCopoeia (Rockville,
MD, USA). The pU6/Neo-p65 shRNA (p65 shRNA) that
targets the sequence GCCCTATCCCTTTACGTCA and
the shRNA scrambled control clone for pU6/Neo were
obtained from GenePharm Co. Ltd. (Shanghai, China).
Transfection was performed using Lipofectamine 2000
(Qiagen, KJ Venlo, NL, USA) according to the manufac-
turer’s instructions.
Luciferase reporter assay
Before luciferase reporter assay, SK-BR-3 and SK-BR-3/R
cells were infected with previously described viruses or their
corresponding vectors for 72 hours. The human PTEN pro-
moter was cloned into the pGL4 luciferase reporter vector
(PTEN-Luc, Promega, CA, USA). Infected SK-BR-3 (SK-BR-
3/R) cells were cotransfected with p-CMV/Neo-p65 (psi-
U6/Puro-p65 shRNA) and PTEN-Luc, together with a
pGL4 vector, which expresses renilla luciferase as an internal
transfection control for transfection efficiency. The expres-
sion of firefly and renilla luciferases was analyzed 48 h after
transfection using the Dual-Luciferase®Reporter (DLR™)
Assay System (Promega, CA, USA) according to the
manufacturer’s instructions. Relative luciferase activity was
expressed as the firefly luciferase activity normalized with re-
spect to the renilla luciferase activity.
In vivo experiments
Animal experiments were approved by the Laboratory
Animal Ethics Committee of the Fourth Military Med-
ical University and were conducted in accordance with
the Animal Research: Reporting In Vivo Experiments
(ARRIVE) guidelines. 48 female athymic nude mice (4–6
weeks old, 18-25 g) were purchased from experimental
animal center of the Fourth Military Medical University.
MTDH-knockdown SK-BR-3/R cells (1 × 107 cells in
100 μl 50% Matrigel) or MTDH overexpression SK-BR-3
cells were inoculated subcutaneously into the mammary
fat pads of mice as previously described [30]. SK-BR-3/R
cells and SK-BR-3 cells were served as control, respect-
ively. Three weeks later, 12 mice in each group receivedi.p injection of 100 μl trastuzumab solution (10 mg/kg,
n = 6) or 100 μl sterile PBS (n = 6) twice weekly. Tumor
xenografts in each group were measured with calipers
every week. Tumor volume in mm3 was calculated by
the formula: volume = width2 × length/2 [31]. Mice were
sacrificed at week 5. Tumor xenografts were retrieved
for histological examination and immunohistochemical
analysis of PTEN and Ki67 expressions.
Statistical analysis
Numerical data were presented as mean ± standard devi-
ation. The correlations between MTDH expression and
clinical factors were evaluated by Chi square test or
Fisher’s exact test. Associations between variables were
analyzed using the Spearman correlation test. PFS were
compared using the Kaplan–Meier method with the log-
rank test. Comparisons for numerical data were per-
formed using a two-tailed Student’s t test. All statistical
analyses were carried out using the SPSS 16.0 statistical
software (SPSS Inc., Chicago, IL, USA). P value less than
0.05 was considered statistically significant.
Results
MTDH overexpression induced trastuzumab resistance in
HER2 positive breast cancer patients
Detailed characteristics of the 118 patients with HER2 posi-
tive breast cancer were summarized in Table 1. High
MTDH expression was found in over half of these patients
(62.7%). There were varied MTDH expressions in patient
subgroups classified by positive nodal status (P = 0.026), ad-
vanced pathological stage (P = 0.012) and high Ki67 index
(P = 0.033); however, there was no association between
MTDH expression and age, hormone receptor status, or
histological grade. As revealed in Figure 1A, MTDH expres-
sion in tumors was heterogeneous and MTDH had both
cytoplasmic and nuclear localizations. Subgroup analyses
were further performed to investigate the MTDH expression
in 36 patients who received trastuzumab-based first line
therapy. Clinical benefit from trastuzumab was defined as
patients having a complete response, partial response, or
stable disease ≥ 6 months. High MTDH expression was de-
tected in 22 patients, of whom only 8 patients (36.4%) ac-
quired clinical benefit and the median PFS was 6 months. In
contrast, 10 in 14 patients (71.4%) with low MTDH expres-
sion gained clinical benefit and a median PFS 15 months
(Figure 1B and C). There was a trend toward a higher clin-
ical beneficial rate and a longer PFS in patients with low
MTDH expression (P = 0.024).
We further examined the association of MTDH and
PTEN expression in these 36 patients who received
trastuzumab-based therapy. They were divided into two
subgroups according to the treatment response. Interest-
ingly, MTDH expression was significantly lower in
patients who achieved clinical benefit from trastuzumab-
Table 1 Patient characteristics
Variable Total no. MTDH expression P value*
High Low
No. % No. %
Age
<50 40 24 20.3 16 13.6
≥50 78 50 42.4 28 23.7 0.663
Nodal status
Positive 82 58 49.2 24 20.3
Negative 36 16 13.6 20 16.9 0.007
Stage
I 20 7 5.9 13 11.0
II 27 17 14.4 10 8.5
III 25 18 15.3 7 5.9
IV 46 32 27.1 14 11.9 0.038
Grade
1 28 14 11.9 14 11.9
2 43 31 26.3 12 10.2
3 47 29 24.5 18 15.2 0.167
ER status
Positive 66 40 33.9 26 22.0
Negative 52 34 28.8 18 15.3 0.594
PR status
Positive 60 36 30.5 24 20.3
Negative 58 38 32.2 20 17.0 0.536
Ki67
High index 78 52 44.1 23 19.5
Low index 40 22 18.6 21 17.8 0.015
*Chi square test or Fisher’s exact test.
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(P = 0.035). In contrast to decreased MTDH level, PTEN
expression was significantly higher (P = 0.023) in these pa-
tients as compared with patients with progressive diseased
(Figure 1E). Moreover, High MTDH level was correlated
with low PTEN expression in patients with poor clinical
benefit, confirmed by regression analysis (Figure 1F,
r = 0.507, P = 0.002). These results suggest that MTDH
up-regulation is associated with PTEN reduction and tras-
tuzumab resistance in HER2 positive breast cancers.
MTDH overexpression and PTEN reduction protected
trastuzumab-resistant HER2 positive breast cancer cells
from trastuzumab exposure
After continuous exposure to 5 μg/ml trastuzumab for
8 months, HER2 overexpressing breast cancer cells with
trastuzumab resistant (SK-BR-3/R) was successfully devel-
oped. Relative proliferation in SK-BR-3/R cells under trastu-
zumab exposure at different time points was higher than in
SK-BR-3 cells. Dose-dependent trastuzumab cytotoxicity inSK-BR-3 cells was observed, but not obvious in SK-BR-3/R
cells (Figure 2A and B). The relative ratio of MTDH mRNA
was significantly higher in SK-BR-3/R cells. In contrast,
PTEN mRNA was significantly lower in SK-BR-3/R cells
compared with their parental counterparts (Figure 2C).
Moreover, elevated MTDH and p-Akt, but reduced PTEN
expressions were found in SK-BR-3/R cells than in parental
cells by western blot analysis (Figure 2D and E). These find-
ings were further supported by immunofluorescence obser-
vance (Figure 2F), suggesting the implication of MTDH
and PTEN/Akt signaling in trastuzumab resistance.Alterations of MTDH expression regulated trastuzumab
resistance via modulating PTEN/Akt signaling in HER2
positive breast cancer cells
To investigate whether MTDH manipulation modulate
trastuzumab sensitivity, MTDH-shRNA was delivered
into SK-BR-3/R cells and MTDH into SK-BR-3 cells, re-
spectively. As shown in Figure 3A, MTDH-shRNA
effectively blocked MTDH expression in SK-BR-3/R
cells in comparison with control group that were
infected with scrambled shRNA. Moreover, MTDH-
shRNA increased PTEN expression and reduced Akt
phosphorylation, suggesting the inactivation of Akt
signaling. Next, we examined the impact of MTDH-
shRNA on SK-BR-3/R cell survival under trastuzumab
exposure. Down-regulation of MTDH decreased the
viability (Figure 3B) and proliferation (Figure 3C and
Additional file 1: Figure S1) of SK-BR-3/R cells. In
addition, significant increase of apoptosis rate was ob-
served (Figure 3D). Importantly, trastuzumab sensitivity
was recovered in SK-BR-3/R cells infected with MTDH-
shRNA since trastuzumab resumed efficiency at the
concentration of 5 μg/ml, as demonstrated by the re-
sults of cell proliferation and TUNEL assay.
We sought to define whether MTDH overexpression
in SK-BR-3 cells contribute to trastuzumab resistance
using a retrovirus MTDH delivery system. In contrast to
MTDH suppression in trastuzumab resistant cells, over-
expressing MTDH in parental SK-BR-3 cells decreased
PTEN expression and increased Akt phosphorylation
(Figure 3A). Increased MTDH expression was detected
in MTDH-SK-BR-3 cells compared to SK-BR-3 cells in-
fected with empty vectors (Figure 3A). In addition, over-
expressed MTDH not only enhanced the viability
(Figure 3B and Additional file 1: Figure S1) and prolifer-
ation (Figure 3C) in MTDH-SK-BR-3 cells, but also re-
duced the cell apoptosis (Figure 3D). Surprisingly,
MTDH-SK-BR-3 cells acquired resistance to trastuzu-
mab at the concentration of 5 μg/ml. These evidence
supported that MTDH participated in the alteration of
trastuzumab resistance via modulating PTEN expres-
sion in HER2 positive breast cancer cells.
Figure 1 MTDH expression in HER2 positive breast cancer patients was associated with PTEN reduction and trastuzumab resistance.
A. Representative image of MTDH immunohistochemical staining in paraffin-embedded tissue from118 breast cancer patients (IRS =0, 3, 6, 12,
magnification at 400×, scale bar =100 μm); B. The comparison of PFS between patients with high MTDH expression or low MTDH expression. Median
PFS was 6 months in patients with high MTDH expression and 15 months with low MTDH expression. Log Rank test P = 0.024; Patients were treated
with trastuzumab-based first line therapy; C. Different clinical benefit (CB) rates in two subgroups, high MTDH expression (n =22) and low MTDH
expression (n =14) were found (P =0.025); D. MTDH level was negatively correlated with PTEN expression in patients treated with trastuzumab-based
first line therapy; E. The scatter plot of MTDH and PTEN expressions in patients with different clinical benefits; F. The regression analysis of MTDH and
PTEN expressions.
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pathway
PTEN is tightly controlled by various non-genomic
mechanisms, such as transcriptional regulation and
post‑transcriptional regulation by non‑coding RNAs be-
sides PTEN mutation or deletion. Increasing evidence
demonstrates that NFκB signaling directly or indirectly
inhibits PTEN transcription. It is reported that MTDH
activate NFκB by promoting degradation of IκBα and
nuclear translocation of p65. In these contexts, we pos-
tulated that MTDH modulate PTEN expression via
NFκB signaling pathway.Based on this hypothesis, we evaluated the expressions
of IκBα and p65 by western blot analysis in both
MTDH-SK-BR-3 cells and MTDH-shRNA infected SK-
BR-3/R cells. As shown in Figure 4A, the level of IκBα
increased significantly 72 hours after MTDH-shRNA
infection in SK-BR-3/R cell compared with scrambled-
shRNA infected cells. Meanwhile, the levels of p65
increased in cytoplasmic extract and decreased in the
nuclear extract of cells after MTDH-shRNA infection. In
contrast, the level of IκBα increased significantly after
MTDH infection, compared with empty vector infected
SK-BR-3 cells. Consistently, the levels of p65 protein
Figure 2 Elevated MTDH and reduced PTEN expressions in trastuzumab-resistant HER2 positive breast cancer cells. A. Relative proliferation
of SK-BR-3 and SK-BR-3/R cells under trastuzumab exposure (5 μg/ml) at different time points by MTT assay (*P < 0.05); B. Dose-dependent trastuzumab
cytotoxicity in SK-BR-3 cells by MTT assay (*P < 0.05). The proliferation curve of SK-BR-3/R cells was relatively flat, indicating trastuzumab resistance;
C. Real-timeRT-PCR revealed mRNA expression of MTDH is significantly higher in SK-BR-3/R cells, while PTEN expression on the opposite (*P < 0.05);
D. Higher levels of MTDH and p-Akt expressions as well as reduced PTEN expression were detected in SK-BR-3/R cells by western blot analysis; E.
Significant differences in MTDH, PTEN and p-AKt expressions between SK-BR-3 and SK-BR-3/R cells (*P < 0.05); F. The immunofluorescence staining of
SK-BR-3 and SK-BR-3/R cells revealed differential MTDH, PTEN and p-Akt expressions. All in vitro experiments were repeated for three times.
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clear extract of cells after MTDH infection. Immunofluores-
cence staining confirmed the nuclear translocation of p65
following MTDH and MTDH-shRNA infection (Figure 4B).
Next, we performed transient co-transfection experi-
ments to examine whether MTDH regulates PTEN pro-
moter activity via inducing p65 translocation in SK-BR-3
and SK-BR-3/R cells. SK-BR-3 cells were either infected
with MTDH or vector and then transfected with p65
and PTEN-Luc containing NFκB binding sites upstream
of the luciferase gene. Both MTDH infection and p65
transfection suppressed PTEN-Luc activity in SK-BR-3
cells (Figure 4C). Furthermore, PTEN-Luc suppression
by p65 was enhanced by infection of MTDH. On the
other hand, SK-BR-3/R cells were either infected with
MTDH-shRNA or scrambled shRNA and then trans-
fected with p50-shRNA and PTEN-Luc. MTDH-shRNA
infection or p65-shRNA transfection increased PTEN-
Luc activity in SK-BR-3/R cells. Additionally, PTEN-Luc
induction by p65-shRNA was enhanced by infection ofMTDH-shRNA (Figure 4D). All these suggests that p65
suppresses PTEN promoter activity, and MTDH en-
hances PTEN transcriptional suppression by promoting
p65 translocation.
Forced PTEN expression in SK-BR-3/R cells restored
trastuzumab sensitivity
To assess whether restoring PTEN expression in SK-BR-3/
R cells may re-sensitize the cancer cells to trastuzumab
treatment. We transfected SK-BR-3/R cells with plasmid
vector encoding GFP-PTEN and determined the expression
of ectopic GFP-PTEN expression after 48 h of transfection
by Western blot analysis. Ectopic GFP-PTEN expression
driven by a heterologous promoter was not affected by ele-
vated MTDH in SK-BR-3/R cells. (Figure 5A). Aligned with
increased PTEN expression, Akt phosphorylation was re-
duced in these cells. Furthermore, SK-BR-3/R cells with
GFP-PTEN transfection restored trastuzumab sensitivity,
since the cell viability decreased by 65.3% (Figure 5B) and
the cell apoptosis rate increased by 6.5 fold as compared
Figure 3 MTDH manipulation regulated trastuzumab resistance by influencing PTEN and pAkt expression in HER2 positive breast cancer
cells. A. Western blot analysis revealed that MTDH-shRNA blocked MTDH expression accompanied by increased PTEN and reduced p-Akt in SK-BR-3/R
cells. Up-regulation of MTDH in SK-BR-3 cells was also realized accompanied with downregulated PTEN and elevated p-Akt; B. MTT assay indicated that
MTDH-shRNA significantly reduced trastuzumab resistance in SK-BR-3/R cells, while MTDH up-regulation led to the resistance of trastuzumab (5 μg/ml,
72 h) in SK-BR-3 cells (*P < 0.05). MTDH was overexpressed in SK-BR-3 cells and knocked down in SK-BR-3/R cells; C. 5-ethynyl-2′-deoxyuridine (EdU)
incorporation assay demonstrated trastuzumab resistance in MTDH-SK-BR-3 cells but not in engineered SK-BR-3/R cells (*P < 0.05); D. and E. Results of
TUNEL assay denoted higher apoptosis rate in SK-BR-3/R cells interfered by MTDH-shRNA (magnification at 200×, *P < 0.05).
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gether, these data suggested restoring PTEN expression re-
sensitize SK-BR-3/R cells to trastuzumab treatment.
MTDH contributed to trastuzumab resistance in breast
cancer mice model by decreasing PTEN expression
Athymic nude mice bearing breast cancer xenografts were
used to demonstrate whether MTDH-mediated PTEN si-
lence still exerted a pivotal role in trastuzumab resistance
in vivo. Three weeks after subcutaneous inoculation of
breast cancer cells, smaller tumor volumes in MTDH-shRNA group with trastuzumab injection in comparison
with vector control group using SK-BR-3/R cells infected
with scrambled shRNA (Figure 6A and Additional file 2:
Figure S2). Tumor xenografts in MTDH-SK-BR-3 group
outgrew other 3 groups. Compared with vector control
group, tumor volumes were larger in MTDH-SK-BR-3
group treated with trastuzumab (Figure 6B and Additional
file 2: Figure S2). Trastuzumab treatment hardly affected
tumor growth in SK-BR-3/R group. On the contrary, trastu-
zumab retarded the growth of tumor xenografts in MTDH-
shRNA group and SK-BR-3 group. Histological examination
Figure 4 MTDH modulated PTEN expression via NF-κB signaling pathway. A. MTDH downregulation resulted in increased IκBαexpression and
decreased p65 nuclear translocation in SK-BR-3/R cells. High level of PTEN and decreased p-Akt were also observed. MTDH overexpression activated NF-κB
by promoting IκBα degradation and p65 nuclear translocation in SK-BR-3 cells. Decreased PTEN expression and high level of p-Akt were observed. β-actin
and lamin B. were subcellular loading controls for cytoplasmic and nuclear extracts respectively; B. Immunofluorescence imagings of p65 in cells with
MTDH manipulation (magnification at 400×); C. Relative PTEN-Luc activity after co-transfection of p65 and MTDH-shRNA in SK-BR-3/R cells (*P < 0.05);
D. Relative PTEN-Luc activity after co-transfection of p65 and MTDH in SK-BR-3 (*P < 0.05).
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tion confirmed the existence of tumor in these mice. Be-
sides, immunohistochemical analysis revealed diverse PTEN
and Ki67 expressions among these groups (Figure 6C and
Additional file 2: Figure S2). Reduced PTEN and increased
Ki67 expressions were found in MTDH-SK-BR-3 group with
or without trastuzumab treatment, while few Ki67 but dis-
tinct PTEN stainings were observed in MTDH-shRNA
group with trastuzumab injection.
Discussion
Trastuzumab is a humanized monoclonal antibody target-
ing the extracellular domain IV of HER2 and is commonlyapplied for HER2-positive patients. However, trastuzumab
resistance is an intractable problem for both clinicians and
patients since it denotes a poor prognosis that severely
threatens patients’ life. Elucidating the underlying molecu-
lar mechanisms implicated in the resistance transition
may renew the strategies to fight against refractory HER2
positive breast cancer. A wide range of putative mecha-
nisms to trastuzumab resistance based on laboratory ex-
periments have been proposed but most of them still lack
clinical relevance [32,33].
Results of immunohistochemical studies from several
groups reveal diverse MTDH expressions in HER2 posi-
tive breast cancer tissues (ranging from 39% to 65%),
Figure 5 Forced PTEN expression in SK-BR-3/R cells restored trastuzumab sensitivity. A. PTEN expression were retrived and p-Akt was decreased in
SK-BR-3/R cells transfected with GFP-PTEN; B. MTT assay indicated that ectopic PTEN expression in SK-BR-3/R cells reduced cell viability in the absence of
trastuzumab. When trastuzumab was added, cell viability was further inhibited (*P < 0.05); C. TUNEL assay suggested that ectopic expression of PTEN
resensitized the trastuzumab-treated SK-BR-3/R cells to apoptosis (*P < 0.05).
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sion [23,27,29,34]. Moreover, increased MTDH expression
correlates with clinicopathological features including posi-
tive nodal status, distant metastasis, advanced stage, Ki-67
index and predicts a poor patient survival [27,34-36]. Be-
sides, MTDH overexpression increases resistance of HCC
cells to fluorouracil [28]. It is also recognized that MTDH
involves in the resistance of chemotherapeutic drugs in
many other types of cancer, probably through various sig-
naling pathways including PI3K/AKT, Wnt/b-catenin, and
NFκB [21,37,38]. Hu et al. described that knockdown of
MTDH decreased the expressions of chemoresistance
genes and sensitized cancer cells to a broad spectrum of
chemotherapy drugs, including paclitacxel, doxorubicin
and cisplatin [29]. In addition, miR-375 that directly inhib-
ited MTDH expression reversed both tamoxifen resistance
and accompanying epithelial-mesenchymal transition like
properties in tamxifen resistant breast cancer cells [39]. In
consistence with previous findings, clinical data in this
study revealed high MTDH but low PTEN expressions in
HER2 positive breast cancer tissues, and MTDH overex-
pression was related with advanced pathological stage and
Ki-67 index. Moreover, we found that MTDH reverselycorrelated with PTEN expression. Subgroup analyses
proves that MTDH is implicated in trastuzumab resist-
ance in HER2 positive breast cancer, which is further con-
firmed by elevated MTDH but reduced PTEN expressions
in trastuzumab-resistant breast cancer cells. Subsequent
experiments demonstrated MTDH mediates trastuzumab
resistance by decreasing PTEN expression through an
NFκB-dependent pathway, suggesting the potential role of
MTDH as a predictive factor of treatment response to
anti-HER2 therapy.
The PTEN-PI3K/Akt pathway attracts extensive atten-
tions as a target in refractory HER2 positive breast cancer.
Blockade of the PI3K/Akt pathway by PTEN has been re-
ported to induce cell death and apoptosis in trastuzumab
resistant breast cancer cells [40-43]. Upon MTDH modu-
lation in SK-BR-3 and trastuzumab-resistant SK-BR-3/R
cells, we confirmed that MTDH overexpression first acti-
vated NFκB signal and then influenced PTEN expression,
thus maintaining PI3K/Akt signaling pathway in HER2
positive breast cancer, which conferred a survival advan-
tage under trastuzumab exposure. On the other hand,
MTDH down-regulation suppressed the proliferation po-
tential of SK-BR-3/R cells and restored the sensitivity to
Figure 6 MTDH contributed to trastuzumab resistance by decreasing PTEN expression in breast cancer model using athymic nude mice. A.
Smaller tumor volumes in MTDH-shRNA group with trastuzumab injection in comparison with vector control group using SK-BR-3/R cells infected with
scrambled shRNA (*P < 0.05); B. Tumor xenografts in MTDH-SK-BR-3 group outgrew other 3 groups. Compared with vector control group, tumor
volumes were larger in MTDH-SK-BR-3 group than that in Vector-SK-BR-3 group treated with trastuzumab (*P < 0.05); C. Histological examination of
tumor xenografts. Hematoxylin and eosin (HE) staining confirmed the existence of tumor and immunohistochemical analysis revealed distinct Ki67 and
PTEN expressions in xenografts (magnification at 400×).
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[9,10,36,44]. Furthermore, forced PTEN expression in SK-
BR-3/R cells that was not affected by MTDH level, inhibited
PI3K/Akt signaling and restored the trastuzumab sensitivity.
All these supported that acquired resistance to trastuzumab
in SK-BR-3R cells was regulated, at least in part, by MTDH
via influencing PTEN-PI3K/Akt signaling in an NFκB
dependent pathway.
Various down-stream molecules of PTEN-PI3K/Akt sig-
naling pathway involving in trastuzumab resistance have
also been characterized. Chakrabarty et al. found that
trastuzumab-resistant cells relied on a HER2-PI3K-FoxO-
Survivin axis [45]. Wu and colleagues reported that block-
ing the constitutively active Akt significantly increased
FOXO1A expression and rendered the cells vulnerable to
trastuzumab incubation [46]. In Li’s study, FOXO1 could
be downregulated by promoting FOXO1 phosphorylation
via the PI3K/Akt pathway, as a consequence, changing the
expression pattern of cyclin-dependent kinase inhibitors.
Therefore, it is possible to achieve durable responses in
breast cancer refractory to trastuzumab therapy by MTDHinhibition, which functions through PTEN-PI3K/Akt path-
way to realize tumor regression [40]. Xu and associates re-
ported that MTDH mediated tamoxifen resistance through
PTEN-PI3K/Akt pathway in MCF-7 cells [47], but their
study lacks the evidence to reveal the interconnection and
crosstalk between MTDH and PTEN, which was comple-
mented in our study. Given that PTEN is involved in both
tamoxifen-resistance and trastuzumab-resistance [48-50],
more studies are needed to validate whether MTDH is a
general or a specific mechanism of drug resistance and how
it functions in breast cancer.
There are some limitations in our study. Retrospective
data were collected from a single center and patient popu-
lation was not large to form a solid evidence for interpret-
ation and immediate clinical translation.
Conclusions
MTDH overexpression confers trastuzumab resistance in
HER2 positive breast cancer patients, which may also be a
potential predictive factor for the evaluation of clinical re-
sponse to trastuzumab-based anticancer therapy. MTDH
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PTEN-PI3K/Akt signaling in an NFκB dependent pathway
in HER2 positive breast cancer. Future studies are needed
to broaden MDTH inhibition as a therapeutic approach
for the treatment of trastuzumab resistant HER2 positive
breast cancer.
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